Aktis Oncology

Evidence from analogs suggests high willingness to pay if efficacy is compelling. For example, Novartis’ Pluvicto lists at about 51,000 dollars per dose in 2026, with a typical six-dose course implying a quarter-million dollar regimen.

If Aktis delivers superior outcomes on validated targets like Nectin-4 or B7-H3, it could command similar or higher pricing, especially in later-line settings. However, payers increasingly scrutinize high-cost oncology therapies, and radiopharma site-of-care constraints can cap real-world utilization.

Overall latent pricing power is good but contingent on data.